4D Molecular Therapeutics, Inc. Long-Term Debt
4D Molecular Therapeutics, Inc. (FDMT) had Long-Term Debt of $19.59 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermDebtNoncurrent · last filed 2026-08-13
- 2026-06-30: Long-term Debt, Excluding Current Maturities $19.59M.
- 2025-12-31: Long-term Debt, Excluding Current Maturities $0.00.
| Period end | Long-term Debt, Excluding Current Maturities |
|---|---|
| 2026-06-30 | $19.59M 10-Q · filed 2026-08-13 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |